At the news
? BULLISHIMPACT 7/10 COURT-RULING filed Aug 17, 2026 at 20:00 ET
The Fourth Circuit affirmed a preliminary injunction in favor of Gilead Sciences, blocking the importation and sale of foreign-market Gilead-branded drugs (including Biktarvy) by alternative funding programs and their facilitators. The court held that the imported drugs are not 'genuine' under the Lanham Act due to material differences in labeling, warnings, and quality control, and that Gilead is likely to succeed on its direct and contributory trademark infringement claims. This ruling protects Gilead's U.S. pricing power and brand integrity by shutting down a gray-market importation channel that threatened to undercut domestic revenue on key HIV drugs.
- The Fourth Circuit affirmed a preliminary injunction barring the importation, advertising, and sale of foreign-market Gilead-branded medications in the U.S.
- The court found that imported Gilead drugs (e.g., Turkish Biktarvy) are not 'genuine' under the Lanham Act due to material differences in labeling, warnings, and quality-control systems.
- The ruling applies to direct infringers (Rx Valet, Advanced Pharmacy, Affordable Rx, Gregory Santulli) and contributory infringers (Meritain Health, ProAct).
- Gilead is likely to succeed on the merits of its trademark claims, and the injunction protects against irreparable harm to Gilead's goodwill and reputation.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access